Literature DB >> 18482431

Advances in the field of cannabinoid--opioid cross-talk.

Patricia Robledo1, Fernando Berrendero, Andrés Ozaita, Rafael Maldonado.   

Abstract

A remarkable amount of literature has been generated demonstrating the functional similarities between the endogenous opioid and cannabinoid systems. Anatomical, biochemical and molecular data support the existence of reciprocal interactions between these two systems related to several pharmacological responses including reward, cognitive effects, and the development of tolerance and dependence. However, the assessment of the bidirectionality of these effects has been difficult due to their variety and complexity. Reciprocal interactions have been well established for the development of physical dependence. Cross-tolerance and cross-sensitization, although not always bidirectional, are also supported by a number of evidence, while less data have been gathered regarding the relationship of these systems in cognition and emotion. Nevertheless, the most recent advances in cannabinoid-opioid cross-modulation have been made in the area of drug craving and relapse processes. The present review is focused on the latest developments in the cannabinoid-opioid cross-modulation of their behavioural effects and the possible neurobiological substrates involved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18482431     DOI: 10.1111/j.1369-1600.2008.00107.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  43 in total

1.  Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.

Authors:  L Fattore; Ms Spano; V Melis; P Fadda; W Fratta
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 2.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

5.  Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

Authors:  Joost Wiskerke; Nicky Stoop; Dustin Schetters; Anton N M Schoffelmeer; Tommy Pattij
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

6.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

7.  Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone.

Authors:  Christopher J C Rodgman; Christopher D Verrico; Ray B Worthy; Erica E Lewis
Journal:  Prim Care Companion CNS Disord       Date:  2014-08-14

8.  Why Marijuana Will Not Fix the Opioid Epidemic.

Authors:  Kenneth Finn
Journal:  Mo Med       Date:  2018 May-Jun

Review 9.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

10.  PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2.

Authors:  Melisa J Wallace; Philip M Newton; Thomas McMahon; Jacklyn Connolly; Anne Huibers; Jennifer Whistler; Robert O Messing
Journal:  Neuropsychopharmacology       Date:  2009-01-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.